+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Daliresp

  • ID: 4775200
  • Report
  • 16 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Daliresp (roflumilast; AstraZeneca/Allergan/Takeda) is an oral phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of patients with severe chronic obstructive pulmonary disease (COPD), who suffer from chronic bronchitis and frequent exacerbations. PDE4 inhibitors are thought to relax airway smooth muscle, suppress the activation of inflammatory cells, and modulate the activity of pulmonary nerves. Daliresp received US and EU approvals for use in COPD in February 2011 and July 2010, respectively. In January 2011, Mitsubishi Tanabe announced that it had terminated its agreement with Nycomed, and would not pursue further development of roflumilast for respiratory diseases. As such, the author does not forecast Daliresp to launch in Japan.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Daliresp: Chronic obstructive pulmonary disease (COPD)

LIST OF FIGURES
Figure 1: Daliresp for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of Daliresp for COPD
Figure 3: The authors drug assessment summary of Daliresp for COPD
Figure 4: Daliresp sales for COPD across the US and major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Daliresp drug profile
Table 2: Daliresp Phase III data in COPD
Table 3: Daliresp sales for COPD across the US and major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll